Renovaro Biosciences Updates Business Address & Phone on Jan 16
Ticker: LNAI · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Renovaro Biosciences Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, contact-update
TL;DR
**Renovaro Biosciences just updated its official contact info, nothing major.**
AI Summary
Renovaro Biosciences Inc. filed an 8-K on January 16, 2024, to update its business address to 2080 Century Park East, Suite 906, Los Angeles, CA 90067, and its business phone number to +1 (305) 918-1980. This filing also confirms its state of incorporation as Delaware and its IRS Employer Identification No. as 45-2559340. For investors, this matters as it provides current contact information, which is essential for any shareholder communications or due diligence, indicating standard operational updates rather than significant strategic shifts.
Why It Matters
This filing provides updated contact information for Renovaro Biosciences, which is important for investors needing to reach the company or verify its operational details. It signals routine corporate maintenance rather than a major event.
Risk Assessment
Risk Level: low — This filing is purely administrative, updating contact information, and does not introduce any new financial or operational risks.
Analyst Insight
A smart investor would note this administrative update as routine and not indicative of any immediate investment action. It's a good practice to keep company contact information current for due diligence.
Key Players & Entities
- Renovaro Biosciences Inc. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for Renovaro Biosciences Inc.
- 45-2559340 (dollar_amount) — IRS Employer Identification No. for Renovaro Biosciences Inc.
- 2080 Century Park East, Suite 906 Los Angeles, CA 90067 (company) — new principal executive offices address
- +1 (305) 918-1980 (dollar_amount) — new registrant's telephone number
FAQ
What is the primary purpose of Renovaro Biosciences Inc.'s 8-K filing on January 16, 2024?
The primary purpose of the 8-K filing on January 16, 2024, is to report an 'Other Event' and 'Financial Statements and Exhibits,' specifically updating the registrant's business address and telephone number.
What is the new business address for Renovaro Biosciences Inc. as reported in this filing?
The new business address for Renovaro Biosciences Inc. is 2080 Century Park East, Suite 906, Los Angeles, CA 90067.
What is the updated telephone number for Renovaro Biosciences Inc.?
The updated telephone number for Renovaro Biosciences Inc. is +1 (305) 918-1980.
What is Renovaro Biosciences Inc.'s state of incorporation and IRS Employer Identification No. according to the filing?
Renovaro Biosciences Inc.'s state of incorporation is Delaware, and its IRS Employer Identification No. is 45-2559340.
Does this 8-K filing indicate any changes in the company's registered securities or trading symbols?
No, the filing lists 'Title of Each Class', 'Trading Symbol', and 'Name of Each Exchange on Which Registered' but does not specify any changes to these, only confirming that securities are registered pursuant to Section 12(b) of the Act.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-16 08:06:32
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
Filing Documents
- e5345_8k.htm (8-K) — 29KB
- e5345_ex99-1.htm (EX-99.1) — 32KB
- e5345_ex99-2.htm (EX-99.2) — 18KB
- ex_001.jpg (GRAPHIC) — 64KB
- ex_002.jpg (GRAPHIC) — 559KB
- ex_003.jpg (GRAPHIC) — 137KB
- ex_004.jpg (GRAPHIC) — 225KB
- ex_005.jpg (GRAPHIC) — 194KB
- ex_006.jpg (GRAPHIC) — 131KB
- ex_007.jpg (GRAPHIC) — 315KB
- ex_008.jpg (GRAPHIC) — 213KB
- ex_009.jpg (GRAPHIC) — 257KB
- ex_010.jpg (GRAPHIC) — 173KB
- ex_011.jpg (GRAPHIC) — 235KB
- ex_012.jpg (GRAPHIC) — 354KB
- ex_013.jpg (GRAPHIC) — 335KB
- ex_014.jpg (GRAPHIC) — 238KB
- ex_015.jpg (GRAPHIC) — 228KB
- ex_016.jpg (GRAPHIC) — 269KB
- ex_017.jpg (GRAPHIC) — 255KB
- ex_018.jpg (GRAPHIC) — 141KB
- ex_019.jpg (GRAPHIC) — 138KB
- ex_020.jpg (GRAPHIC) — 165KB
- ex_021.jpg (GRAPHIC) — 172KB
- ex_022.jpg (GRAPHIC) — 276KB
- ex_023.jpg (GRAPHIC) — 277KB
- ex_024.jpg (GRAPHIC) — 240KB
- ex_025.jpg (GRAPHIC) — 287KB
- ex_026.jpg (GRAPHIC) — 279KB
- ex_027.jpg (GRAPHIC) — 403KB
- ex_028.jpg (GRAPHIC) — 133KB
- 0001731122-24-000076.txt ( ) — 9478KB
- renb-20240116.xsd (EX-101.SCH) — 3KB
- renb-20240116_lab.xml (EX-101.LAB) — 33KB
- renb-20240116_pre.xml (EX-101.PRE) — 22KB
- e5345_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 16, 2024, Renovaro Biosciences Inc. (the " Company ") published a letter to shareholders. A copy of the letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Additionally, on January 16, 2024, the Company made available on its website an investor presentation, which is furnished as Exhibit 99.2 to this Current report on Form 8-K. The information included in this Item 8.01 and in Exhibits 99.1 and 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements
Item 9.01 Financial Statements and Exhibits (d) Exhibits: EXHIBIT NO. DESCRIPTION LOCATION 99.1 Shareholder Letter dated January 16, 2024 Furnished herewith 99.2 Investor Presentation Furnished herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO BIOSCIENCES INC. By: /s/ Luisa Puche Name: Luisa Puche Title: Chief Financial Officer Date: January 16, 2024